Author(s)’ Reply: Is MYCN Overexpression Associated With Poor Outcome in MYCN Non-Amplified Neuroblastomas?

Abstract

Get full access to this article

View all access options for this article.

References

Zhao

Liu

, et al. Prominent staining of MYCN immunohistochemistry predicts a poor prognosis in MYCN non-amplified neuroblastoma. Pediatr Dev Pathol. 2023;26:124-132.

Chang

Yang

, et al. The prognostic roles of and correlation between ALK and MYCN protein expression in neuroblastoma. J Clin Pathol. 2020;73:154-161.

Santiago

Polanco

Fuentes-Alabi

, et al. Multinational retrospective central pathology review of neuroblastoma: lessons learned to establish a regional pathology referral center in resource-limited settings. Arch Pathol Lab Med. 2021;145:214-221.

Chan

Gallie

DeBoer

, et al. MYCN protein expression as a predictor of neuroblastoma prognosis. Clin Cancer Res. 1997;3:1699-1706.

Valentijn

Koster

Haneveld

, et al. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc Natl Acad Sci USA. 2012;109:19190-19195.

Yang

Zhao

Zhang

, et al. MYCN protein stability is a better prognostic indicator in neuroblastoma. BMC Pediatr. 2022;22:404.

Kawano

Hazard

Chiu

, et al. Stage 4S neuroblastoma: molecular, histologic, and immunohistochemical characteristics and presence of 2 distinct patterns of MYCN protein overexpression-a report from the children’s oncology group. Am J Surg Pathol. 2021;45:1075-1081.